cagrilintide drug Cagrilintide (10mg vials) - Peptide

For example, starting at 0.25mg for 4 weeks (using 1mg total) and then switching to 0.5mg for the remaining time would use 1mg plus roughly 1.5mg in the next 3 weeks, totaling 2.5mg from one vial within the 28-day stability window

The replacements of Tyr 2 by residues with restricted flexibility were deleterious for activity

Not intended for diagnostic or therapeutic use

Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The handling editor declared a past co-authorship with the authors

10.1007/s13277-014-1774-7 53 HuangW